<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="11527">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01809106</url>
  </required_header>
  <id_info>
    <org_study_id>Studio CERP</org_study_id>
    <nct_id>NCT01809106</nct_id>
  </id_info>
  <brief_title>RCT Comparing the Analgesic Efficacy of 4 Therapeutic Strategies Based on 4 Different Major Opioids (Fentanyl, Oxycodone, Buprenorphine vs Morphine) in Cancer Patients With Moderate/Severe Pain, at the Moment of Starting 3rd Step of WHO Analgesic Ladder.</brief_title>
  <acronym>CERP</acronym>
  <official_title>RCT Comparing the Analgesic Efficacy of 4 Therapeutic Strategies Based on 4 Different Major Opioids (Fentanyl, Oxycodone, Buprenorphine vs Morphine) in Cancer Patients With Moderate/Severe Pain, at the Moment of Starting 3rd Step of WHO Analgesic Ladder.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mario Negri Institute for Pharmacological Research</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Mario Negri Institute for Pharmacological Research</source>
  <oversight_info>
    <authority>Italy: The Italian Medicines Agency</authority>
    <authority>Italy: Ethics Committee</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Pain, in neoplastic disease, is a symptom with severe negative impact on the quality of life
      of patients and a high incidence, with values around 70-90% in advanced and metastatic
      stages. Than 20 years the main reference for the pharmacological treatment of cancer pain
      are the guidelines produced by the World Health Organization (WHO). This document shows that
      the use of opioid drugs is the mainstay of treatment, with particular reference to opioids
      &quot;major&quot; (3 rd step of the analgesic ladder). The 4 opioids more most commonly prescribed in
      Italy (oral morphine and oxycodone, fentanyl and buprenorphine transdermal), based on the
      data currently available, have an analgesic effect would partly overlap but with different
      percentages of non-responders (NR), a different need to increase the dose over time to
      maintain adequate analgesia, a different action to the switch to another molecule for
      ineffectiveness analgesic. The observations described suggest that opioids, although they
      belong to the same family drug may not be fully comparable with regard to the clinical
      effects products. Important differences are known on the pharmacokinetic and pharmacodynamic
      and, more recently, also in terms of pharmacogenomics. This is a comparative study of
      analgesic strategies based on the use of the 4 mentioned opioids, going to look for possible
      differences in terms of analgesic efficacy, changes in dose over time, use of switch or
      permanent abandonment of treatment, parallel to the contour of the side effects. The
      associated sub-project will link the structure gene of patients and clinical results have
      emerged.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>April 2011</start_date>
  <completion_date type="Anticipated">July 2014</completion_date>
  <primary_completion_date type="Anticipated">July 2014</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Proportion of Non-Responder (NR) patients</measure>
    <time_frame>28 days</time_frame>
    <safety_issue>No</safety_issue>
    <description>Evaluation of the proportion of Non-Responder (NR) patients.  NR correspond to the subjects  who do not report any analgesic effects, with a P.I.D. (pain intensity difference) from visit 6 and visit 1  =/&lt; 0%,  (using a 0-10 NRS ).  It includes the situations of average pain intensity &quot;stable&quot; or &quot;worsened&quot; at day 28 compared with baseline values.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Proportion of full-responder</measure>
    <time_frame>28 days</time_frame>
    <safety_issue>No</safety_issue>
    <description>Evaluation of the proportion of subjects who report full analgesia (full responders: FR). FR is operationally defined as a patient  with  a P.I.D.  =/&gt; 30%   from visit 6 and visit 1  (NRS 0 to 10).</description>
  </secondary_outcome>
  <other_outcome>
    <measure>The opioid escalation index</measure>
    <time_frame>28 days</time_frame>
    <safety_issue>No</safety_issue>
    <description>The proportion of subjects with an increase of opioid daily dose &gt; 5% compared with the basal dosage (OEI%).</description>
  </other_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">600</enrollment>
  <condition>Cancer</condition>
  <condition>Cancer Pain</condition>
  <arm_group>
    <arm_group_label>Morphine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Oxycodone</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Buprenorphine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Fentanyl</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Morphine</intervention_name>
    <description>60 mg /24 ore</description>
    <arm_group_label>Morphine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fentanyl</intervention_name>
    <description>25 microg/h</description>
    <arm_group_label>Fentanyl</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Buprenorphine</intervention_name>
    <description>35 microg/h</description>
    <arm_group_label>Buprenorphine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oxycodone</intervention_name>
    <description>40 mg /24 ore</description>
    <arm_group_label>Oxycodone</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  patients with diagnostic (histological or cytological) evidence of locally advanced
             or metastatic   solid  tumour;

          -  with average  pain intensity  ≥ 4,  measured with NRS and related to the last 24
             hours, due to the cancer, requiring for the first time an analgesic treatment with
             3rd step/WHO opioids

          -  with life expectancy &gt; one month

          -  &quot;strong&quot; opioid naïve;

          -  eligible to take any of the medications under evaluation, by TDS or  by mouth;

          -  with age ≥ 18 years;

        Exclusion Criteria:

          -  Patients recruited in other researches that conflict or may confound the conduction
             and results of the present study;

          -  Lack of informed consent;

          -  with presence of other diseases, including psychiatric/mental illness, severe senile
             or other form of dementia, that can interfere with participation and compliance with
             the study protocol or can contraindicate the use of the investigational drugs;

          -  with presence of co-morbidities, which could create potentially dangerous drug
             interactions with opioids (eg, use of macrolide antibiotics or antifungal,….);

          -  any kind of contraindications to the use of opioid drugs;

          -  Patients with a known story, past or current,  of drugs abuse or addiction;

          -  Use of drugs which presents a combination of opioids and other molecule (as NSAIDs,
             paracetamol, naloxone, ..);

          -  Patients who cannot guarantee regular follow-up visits for logistic or geographic
             reasons;

          -  Need of starting 3rd step treatment in an &quot;emergency clinical situation&quot; that do not
             allow the correct procedures of randomization;

          -  diagnosis of primary brain tumor or leukaemia;

          -  diagnosis of chronic renal failure;

          -  patients with antalgic radiotherapy or radio-metabolic  therapy in progress or
             completed less than 14 days before study;

          -  patients starting a first line chemotherapy simultaneously to the beginning of the
             study;

          -  other types of analgesic treatments, including local-regional anesthetic techniques
             or neurosurgical /ablative methods.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Oscar Corli, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mario Negri Institute of Pharmacological Research - IRCCS</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Oscar Corli, MD</last_name>
    <email>oscar.corli@marionegri.it</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Anna Roberto, Biol Sci D</last_name>
    <email>anna.roberto@marionegri.it</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Arcispedale S. Maria Nuova Azienda Ospedaliera</name>
      <address>
        <city>Reggio Emilia</city>
        <state>RE</state>
        <zip>42100</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>ERMANNO RONDINI, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ospedale S. Marta</name>
      <address>
        <city>Catania</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Sergio Chisari, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Fondazione IRCCS - Istituto Nazionale dei Tumori</name>
      <address>
        <city>Milano</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Augusto Caraceni, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Istituto Scientifico San Raffaele</name>
      <address>
        <city>Milano</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>manuela Pacchioni, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera Valtellina-Valchiavenna</name>
      <address>
        <city>Morbegno</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Donato Valenti, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ospedale Civile di Piacenza</name>
      <address>
        <city>Piacenza</city>
        <zip>29100</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Luigi Cavanna, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Multimedica</name>
      <address>
        <city>Sesto San Giovanni</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Ornella Gottardi, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ospedale San Giovanni Battista di Torino</name>
      <address>
        <city>Torino</city>
        <zip>10126</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Libero Ciuffreda, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ospedale Gradenigo</name>
      <address>
        <city>Torino</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Alessandro Comandone, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <link>
    <url>http://crc.marionegri.it/cancerpain/</url>
    <description>Info of the study</description>
  </link>
  <reference>
    <citation>Apolone G, Bertetto O, Caraceni A, Corli O, De Conno F, Labianca R, Maltoni M, Nicora M, Torri V, Zucco F; Cancer Pain Outcome Research Study Group. Pain in cancer. An outcome research project to evaluate the epidemiology, the quality and the effects of pain treatment in cancer patients. Health Qual Life Outcomes. 2006 Feb 2;4:7.</citation>
    <PMID>16457716</PMID>
  </reference>
  <reference>
    <citation>Apolone G, Corli O, Caraceni A, Negri E, Deandrea S, Montanari M, Greco MT; Cancer Pain Outcome Research Study Group (CPOR SG) Investigators. Pattern and quality of care of cancer pain management. Results from the Cancer Pain Outcome Research Study Group. Br J Cancer. 2009 May 19;100(10):1566-74. doi: 10.1038/sj.bjc.6605053. Epub 2009 Apr 28.</citation>
    <PMID>19401688</PMID>
  </reference>
  <reference>
    <citation>Greco MT, Corli O, Montanari M, Deandrea S, Zagonel V, Apolone G; Writing Protocol Committee; Cancer Pain Outcome Research Study Group (CPOR SG) Investigators. Epidemiology and pattern of care of breakthrough cancer pain in a longitudinal sample of cancer patients: results from the Cancer Pain Outcome Research Study Group. Clin J Pain. 2011 Jan;27(1):9-18. doi: 10.1097/AJP.0b013e3181edc250.</citation>
    <PMID>20842024</PMID>
  </reference>
  <reference>
    <citation>Apolone G, Deandrea S, Montanari M, Corli O, Greco MT, Cavuto S. Evaluation of the comparative analgesic effectiveness of transdermal and oral opioids in cancer patients: a propensity score analysis. Eur J Pain. 2012 Feb;16(2):229-38. doi: 10.1002/j.1532-2149.2011.00020.x. Epub 2011 Dec 19.</citation>
    <PMID>22323375</PMID>
  </reference>
  <reference>
    <citation>Corli O, Montanari M, Deandrea S, Greco MT, Villani W, Apolone G. An exploratory analysis on the effectiveness of four strong opioids in patients with cancer pain. Pain Med. 2012 Jul;13(7):897-907. doi: 10.1111/j.1526-4637.2012.01408.x. Epub 2012 Jun 8.</citation>
    <PMID>22680789</PMID>
  </reference>
  <verification_date>March 2014</verification_date>
  <lastchanged_date>March 25, 2014</lastchanged_date>
  <firstreceived_date>March 8, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>cancer pain</keyword>
  <keyword>major opioid</keyword>
  <keyword>analgesics</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Analgesics</mesh_term>
    <mesh_term>Buprenorphine</mesh_term>
    <mesh_term>Fentanyl</mesh_term>
    <mesh_term>Morphine</mesh_term>
    <mesh_term>Oxycodone</mesh_term>
    <mesh_term>Analgesics, Opioid</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
